AOAlexander Oscar

Alexander Oscar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexander Oscar has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A comparative study of visual outcomes and patient satisfaction with Evolux™, monofocal, and extended depth of focus intraocular lenses

    by Yani Zdravkov, Radomir Dzhambazov, Nevyana Veleva, Vasil Haykin, Alexander Oscar

    This retrospective study aimed to evaluate the postoperative visual acuity and overall patient satisfaction of three groups of patients who underwent cataract surgery. A total of 56 patients and 67 eyes were evaluated and divided based on the type of intraocular lens (IOL) implanted. The evaluation consisted of examining visual acuity at far and intermediate distances preoperatively and postoperatively. On the 30 th postoperative day, contrast sensitivity was evaluated using the Pelli-Robson chart, and all patients completed a questionnaire addressing patient satisfaction at far and intermediate distances, dependence on spectacles, occurrence of halos and glare, and driving difficulties. The present study highlights a clinically relevant intermediate vision advantage of the Evolux™ enhanced monofocal IOL over a standard monofocal IOL while maintaining comparable distance visual acuity and contrast sensitivity. Although extended depth of focus (EDOF) IOLs provided superior intermediate visual acuity, they were associated with lower contrast sensitivity and more frequent photic phenomena in this cohort. The study highlights that enhanced monofocal IOLs may represent a useful compromise between the limited intermediate vision of conventional monofocal lenses and the optical trade-offs associated with EDOF lenses. Larger prospective studies with standardized patient-reported outcome measures and longer follow-up are warranted.

  • Open Access

    Pharmacological, Optical, and Combined Approaches to Myopia Control in Bulgarian Children: A Longitudinal Study

    by G. Dimitrov, G. Dimitrova, A. Levi, N. Veleva, O. Mladenov, Y. Kaneva, A. Oscar

    This study presents different treatments, including both medication and glasses, that affect the progression of myopia in children over time. A total of 250 children aged 6 to 16 were evaluated for a period of 36 months. For the purpose of the study, four groups were formed: one group of pediatric patients receiving low-dose atropine (0.01%), another group wearing defocus-modifying glasses, a third group receiving both treatments, and a control group with no treatment. Key biometric indicators, such as axial length, spherical equivalent, and best-corrected visual acuity, were measured at the start of the study and after that every six months. Non-parametric statistical methods were used to compare changes within each group over time and to identify differences between groups. The protocol achieved high data completeness and showed significant changes within the groups (p<0.001). Clear differences between groups appeared after 12 months. The results suggest that combining atropine and defocus lenses is most effective in slowing myopia progression while maintaining good vision.

  • Open Access

    Screening outcomes and treatment patterns of retinopathy of prematurity in Bulgaria: Emerging role of anti-VEGF therapy

    by Alexander Oscar, Yani Zdravkov, Ognyan Mladenov, Valentina Tomova, Ralitza Georgieva, Vasil Haykin

    A retrospective analysis of premature infants screened for retinopathy of prematurity (ROP) in Sofia between 2019 and 2023 included 660 infants. ROP was diagnosed in 145 infants (21.97%). Treatment was required in 97 infants (14.7% of all screened). Laser photocoagulation was performed in 80 infants (82.5% of treated cases), whereas intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy with aflibercept was administered in 17 infants (17.5%), mainly in posterior or aggressive disease. Spontaneous regression occurred in 48 infants (33.1%). No cases of endophthalmitis or systemic adverse events were observed after anti-VEGF therapy. Lower gestational age and birth weight were strongly associated with disease occurrence. These findings indicate that ROP remains a significant clinical challenge in premature infants, whereas pharmacological VEGF inhibition represents an important therapeutic option in selected severe cases, complementing conventional laser treatment.

  • Open Access

    Cataract after laser treatment of retinopathy of prematurity – challenges in pediatric ophthalmology

    by Alexander Oscar, Radomir Dzhambazov, Nevyana Veleva, Vasil Haykin, Yani Zdravkov

    Retinopathy of prematurity (ROP) is one of the most serious eye diseases affecting prematurely born infants. Modern treatment methods, including laser photocoagulation, have significantly reduced the incidence of blindness and severe visual impairment due to tractional retinal detachment, macular folds, or excessive myopia. However, long-term complications are still observed in some patients, among which cataract formation holds particular significance. The aim of this study was to evaluate the risk of cataract development in premature infants treated for type 1 ROP. We performed a retrospective study during which we studied 660 premature infants (352 boys and 308 girls) for a period of 5 years. Of these, 145 children (21.97%) were diagnosed with ROP at different stages. A total of 97 children (66.9% of those with ROP) underwent treatment for type 1 ROP. Of these, 80 were treated with laser photocoagulation, and 17 with intravitreal anti-VEGF medications. In the remaining 48 children, spontaneous regression of the disease occurred, and no treatment was necessary. During the study period, only one child (1.25%) developed a cataract. The proper balance between laser energy and number of laser spots is crucial for avoiding complications such as cataract formation. Laser therapy for ROP saves the vision of thousands of children worldwide, but it carries a risk of later complications, including cataract formation. Early detection, along with appropriate surgical treatment, optical correction, and occlusion therapy, is crucial for amblyopia prevention and normal visual development. These patients require long-term follow-up and multidisciplinary care to ensure maximum visual potential.